Business
Appointment of Broker
Appointment of Broker.
About this update from Coiled Therapeutics Plc
[{"type":"text","content":"\n\n20 June 2024\n \nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\")\nAppointment of Broker\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth immuno-oncology market, is pleased to announce the appointment of SP Angel Corporate Finance LLP as its broker with immediate effect.\n-ENDS-\nEnquiries:\n\n\n\n\nRoquefort Therapeutics plc\n\n\n+44 (0)20 3918 8633\n\n\n\n\nStephen West (Chairman) / Ajan Reginald (CEO)\n\n\n\n\n\n\n\nSP Angel Corporate Finance LLP (Broker)\nJeff Keating / David Hignell / Vadim Alexandre\n \n\n\n+44 (0) 20 3470 0470\n \n\n\n\n\nBuchanan (Public Relations)\nBen Romney / Jamie Hooper / George Beale\n \n\n\n+44 (0)20 7466 5000\n \n\n\n\n\nPeak IR (Investor Relations)\nSeb Wykeham\n\n\n+33 (0)7 44 44 15 42\n\n\n\n\n \nLEI: 254900P4SISIWOR9RH34\n \nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth immuno-oncology segment prior to partnering or selling to big pharma.\n \nRoquefort Therapeutics' portfolio consists of five novel, patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:\n· Midkine antibodies with significant in vivo efficacy and toxicology studies;\n· Midkine RNA therapeutics with novel anti-cancer gene editing action;\n· Midkine mRNA therapeutics with novel anti-cancer approach;\n· STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and\n· MK cell therapy with direct and NK-mediated anti-cancer action\n \nFor further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on X (formerly Twitter).\n \n\n","length":5384,"tagName":"div"}]